WD, AVOT, LOR, PWRM, RPT - CRWEpicks.com Stock News & Alerts!
_____
Walker & Dunlop, Inc Common Sto (NYSE:WD) announced that on December 29, 2010, it provided $104.7 million of acquisition funding to Ark Holding Company for the purchase of 18 skilled nursing facilities located in South Carolina, North Carolina and Georgia. This transaction represents Walker & Dunlop's second large-scale skilled nursing financing in 2010 exceeding $100 million. In August 2010, Walker & Dunlop funded a 16 facility refinance of the IBHSAR facilities in Florida for $162.2 million.
Walker & Dunlop, LLC, a real estate finance, and delegated underwriting and servicing company, provides advisory, financing, and investment services to commercial real estate investors, owners, and developers in the Mid-Atlantic region.
_____
American Video Teleconferencing Corp. Provides Update
American Video Teleconferencing Corp. (Pink Sheets:AVOT) is pleased to announce that it has hired a French speaking geologist to search the archives of the Quebec Department of Mines for Rare Earths showings not on a current computer file.
Also the company will not be proceeding with the option agreement on the three claim blocks in Northern Saskatchewan as announced on Nov. 29, 2010.
The company believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings.
As neither the Federal nor Quebec Governments have carried out any air borne surveys in this area, the company will seek a contractor to do an air borne Mag-EM radiometric survey.
This survey will cover its present holdings and the immediate surrounding area looking for future acquisitions. We are pleased to be working in the Province of Quebec as it is rated the number one jurisdiction in the world to carry out mineral exploration.
The Quebec Government gives a rebate up to 45% for property expenditures.
Presently the company is in the final stage of negotiations with Kondor Gold Pyt. in Australia.
The company will aggressively continue to search world-wide for opportunities in Precious, Base and Rare Earths metal projects.
_____
Lazard World Dividend & Income Fund Inc. (NYSE:LOR) announced pursuant to its level distribution policy, as previously authorized by its Board of Directors, a monthly distribution of $0.07530, equivalent to 6.5% of the Fund’s net asset value per share as of the close of markets on December 31, 2010 on the Fund’s outstanding common stock. The next distribution is payable on January 24, 2011 to shareholders of record on January 12, 2011. The ex-dividend date is January 10, 2011.
Lazard World Dividend & Income Fund Inc. is a close ended equity mutual fund launched and managed by Lazard Asset Management LLC. The fund invests in the public equity markets across the globe.
_____
PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).
PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.
Alzheimer’s is one, among the common sort of dementia, an over-all term regarding loss of memory and various other intellectual abilities serious enough to interfere with routine daily life. Alzheimer’s condition is the reason for fifty to seventy per cent of dementia cases.
Alzheimer’s disease just isn’t an everyday aspect of increasing age, although the most significant identified risk factor is increasing age, and the most of individuals with Alzheimer’s are 65 and older. Alzheimer’s is just not a illness connected with senior years. As much as five percentage of people with the actual condition have early-onset Alzheimer’s (also called younger-onset), which frequently appears when someone is in an individual’s 40s or 50s.
The NuroPro Blood Test is PWRM’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease .
PWRM’s BC-SeraPro(TM) is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to PWRM’s patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis. Probability score is ranged from 0.0 to 1.0. Results of PWRM’s BC-SeraPro(TM) test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
Breast cancer (malignant breast neoplasm) is normally cancer originating from breast tissue, most frequently of the inside lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts these are known as ductal carcinomas; cancer originating from lobules are known as lobular carcinomas.
Internationally, breast cancer makes up 10% of all cancer incidences among females, defining it as the most frequent kind of non-skin cancer in women and also the 5th highest reason for cancer death. In 04, cancer of the breast caused 519,000 fatalities world-wide (7% associated with cancer deaths; almost 1% of all deaths). Cancer of the breast is about a hundred times more widespread in women compared to men, although men are prevelant to have poorer success on account of waiting times in medical diagnosis.
PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.
_____
Ramco-Gershenson Properties Trust (NYSE:RPT) announced to that it will release its fourth quarter and year-end 2010 results after the market closes on Monday, February 14, 2011.
It will conduct a conference call on Tuesday, February 15, 2011, at 9:00 a.m. eastern time. Shareholders and interested parties may access the call. A replay will be available through February 22, 2011, by dialing 877-660-6853, account #286 and conference ID #364779. A replay will also be archived at the aforementioned web sites for ninety days.
Ramco-Gershenson Properties Trust, a real estate investment trust (REIT), engages in the ownership, development, acquisition, management, and leasing of community shopping centers.
_____
*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates to receive 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTC:AVOT) from the company for 12 months IR Services.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.